InterCure Ltd. (INCR) vs PDS Biotechnology Corporation (PDSB)

A side-by-side comparison of InterCure Ltd. and PDS Biotechnology Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — INCR vs PDSB

growth of $100 · dividends reinvested · last 8y
INCR -68.0% (-13.3%/yr)PDSB -85.6% (-21.5%/yr)INCR compounded faster over this window
0100200Start $100202120232025$32$14
INCR PDSB

INCR vs PDSB: by the numbers

  • •INCR is the larger company ($64M vs $60M market cap).
  • •Both run net losses; PDSB's is the smaller (0.00% vs -13.72% net margin).

Metrics side by side

Valuation

MetricINCRPDSB
P/S ratio0.80N/A
P/B ratio0.51N/A
FCF yield11.56%N/A

Profitability

MetricINCRPDSB
Gross margin14.40%0.00%
Operating margin2.49%0.00%
Net margin-13.72%0.00%
ROE-8.80%N/A
ROIC-4.72%-3699.99%

Growth (annualized)

MetricINCRPDSB
Revenue CAGR (5Y)32.71%N/A
Total return CAGR (5Y)-30.85%-39.13%

Frequently asked

How have INCR and PDSB total returns compared?
Over the past 5 years, INCR delivered -30.85% and PDSB delivered -39.13% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.